Myriad Genetics, Inc. (LON:0K3W)

Market Cap	361.79M -61.0%
Revenue (ttm)	613.97M +0.2%
Net Income	-297.95M
EPS	-3.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	208.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26
Average Volume	561
Open	5.17
Previous Close	5.24
Day's Range	5.17 - 5.31
52-Week Range	3.76 - 15.13
Beta	1.89
RSI	33.67
Earnings Date	Feb 24, 2026

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious o...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K3W

Financial Performance

In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.

Financial numbers in USD